Use of HBV RNA and to predict change in serological status and disease activity in CHB. Read more about Use of HBV RNA and to predict change in serological status and disease activity in CHB.
Serum bile acids as a prognostic biomarker in biliary atresia following Kasai portoenterostomy. Read more about Serum bile acids as a prognostic biomarker in biliary atresia following Kasai portoenterostomy.
Introducing Norah Terrault, MD, MPH, Our 2023 AASLD President. Read more about Introducing Norah Terrault, MD, MPH, Our 2023 AASLD President.
Model to predict major complications following liver resection for HCC in patients with metabolic syndrome. Read more about Model to predict major complications following liver resection for HCC in patients with metabolic syndrome.
Serum biomarkers correlated with liver stiffness assessed in a multicenter study of pediatric cholestatic liver disease. Read more about Serum biomarkers correlated with liver stiffness assessed in a multicenter study of pediatric cholestatic liver disease.
Next-generation pathology detection of T cell-antigen-presenting cell immune synapses in human liver allografts. Read more about Next-generation pathology detection of T cell-antigen-presenting cell immune synapses in human liver allografts.
HBV transcription and translation persist despite viral suppression in HBV-HIV co-infected patients on antiretroviral therapy. Read more about HBV transcription and translation persist despite viral suppression in HBV-HIV co-infected patients on antiretroviral therapy.
Risk of variceal hemorrhage and pretransplant mortality in children with biliary atresia. Read more about Risk of variceal hemorrhage and pretransplant mortality in children with biliary atresia.
Changes in serum hepatitis B surface and e antigen, interferon-inducible protein 10, and aminotransferase levels during combination therapy of immune-tolerant chronic hepatitis B. Read more about Changes in serum hepatitis B surface and e antigen, interferon-inducible protein 10, and aminotransferase levels during combination therapy of immune-tolerant chronic hepatitis B.
Incidence and prediction of HBsAg seroclearance in a prospective multi-ethnic HBeAg-negative chronic hepatitis B cohort. Read more about Incidence and prediction of HBsAg seroclearance in a prospective multi-ethnic HBeAg-negative chronic hepatitis B cohort.
